Journal Article

A New Combination Immunotherapy in Advanced Melanoma

  • Frampton A
  • Sivakumar S
New England Journal of Medicine (2022) 386(1) 91-92
DOI: 10.1056/nejme2116892
18Citations
Citations of this article
33Readers
Mendeley users who have this article in their library.
Get full text

Abstract

With combination immunotherapy, the 5-year survival of patients with advanced melanoma is now approximately 50%. Outcomes can still be further improved, and evaluating new immune checkpoint targets...

Cite

CITATION STYLE

APA

Frampton, A. E., & Sivakumar, S. (2022). A New Combination Immunotherapy in Advanced Melanoma. New England Journal of Medicine, 386(1), 91–92. https://doi.org/10.1056/nejme2116892

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free